GlassScriptPhysician profile
Randi Hummel
NPI 1386005635
$14,095.11
in general payments reported to CMS, 2019-2025
32 companies · $3,629 in 2025
The $3,629 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,218 · 2022: $1,955 · 2023: $2,649 · 2024: $3,644 · 2025: $3,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,906 · Education: $16.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,905.79 |
| Education | $16.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,000.58 | 2021-2025 | |
| Janssen Biotech, INC. | $2,164.67 | 2021-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,885.78 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $875.39 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $735.05 | 2022-2025 | |
| Pfizer INC. | $710.25 | 2021-2025 | |
| Gilead Sciences, INC. | $668.94 | 2021-2025 | Epclusa, Livdelzi |
| Ironwood Pharmaceuticals, INC | $396.17 | 2021-2024 | Linzess |
| Lilly USA, LLC | $352.16 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $349.94 | 2021-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $319.18 | 2021-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $245.82 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $244.88 | 2024-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $175.55 | 2022 | |
| Intercept Pharmaceuticals, INC. | $164.94 | 2021-2023 | Ocaliva |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $128.45 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $106.12 | 2021-2023 | |
| Madrigal Pharmaceuticals | $105.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $95.61 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $79.17 | 2024-2025 | Zenpep, Vowst |
| Harmony Biosciences LLC | $48.52 | 2024 | |
| Alfasigma USA, INC. | $41.84 | 2022 | |
| Braintree Laboratories, INC. | $38.21 | 2023-2025 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $24.48 | 2025 | Iqirvo |
| Ethicon US, LLC | $24.38 | 2021 | |
| Novo Nordisk INC | $20.49 | 2025 | Wegovy |
| Amgen INC. | $18.01 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.27 | 2025 | Voquezna |
| Albireo Pharma, INC. | $16.92 | 2023 | Bylvay |
| Celltrion USA INC. | $16.06 | 2024 | Zymfentra |
| Ferring Pharmaceuticals INC. | $13.60 | 2021 | |
| Echosens North America, INC. | $10.72 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Hummel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.